Site Search
Professionals 295 results
Capabilities 70 results
Practice Area
Winston’s Environmental Practice brings decades of experience to our clients. Chaired by Eleni Kouimelis, former assistant regional counsel with USEPA Region 5, our Environmental Practice provides comprehensive services to clients around the globe.
Industry
Winston & Strawn’s Government Contracts & Grants Practice is a nationally recognized, highly regarded group of lawyers with deep experience in handling high-value, and often contentious, government contract disputes, bid protests, and claims across a broad spectrum of industries and issues. Our team also counsels clients on significant regulatory, compliance, and transactional matters—predominantly private equity and M&A deals.
Experience 57 results
Experience
|February 10, 2025
US$600 million Total Play Telecomunicaciones S.A.P.I. de C.V. Offer to Exchange Senior Notes
Experience
|November 12, 2024
Experience
|October 24, 2024
Charlton Aria Acquisition Corp. Announces Closing of $75,000,000 Initial Public Offering
Insights & News 1,770 results
Speaking Engagement
|May 9, 2025
Join Winston & Strawn partners M. Imad Khan and Keerthika M. Subramanian for the upcoming online program “Hot Topics in International Arbitration and Strategic Transactions: Recent Developments and Key Trends in India” hosted by the Practising Law Insititute.
Client Alert
|May 1, 2025
|3 Min Read
April 2025 Executive Order Targets Prescription Drug Price Reduction
On April 15, 2025, President Trump signed an executive order titled “Lowering Drug Prices by Once Again Putting Americans First.” The subject matter of this executive order criss-crosses considerable policy ground in the overall U.S. pharmaceutical distribution chain. The executive order sets forth the administration’s statement of objectives to reduce prescription medication costs by promoting competition and eliminating practices that lead to high drug prices. Referencing regulatory and policy actions from the first Trump administration and the Biden administration’s policy steps, including the Inflation Reduction Act of 2022 aimed at lowering prescription drug prices for Medicare beneficiaries, the executive order sets forth a broad agenda to impact Medicare prescription drug costs, including in the Medicare Part D program.[1] The order directs the Secretary of Health and Human Services (HHS) to propose and seek comment on guidance for the Medicare Drug Price Negotiation Program and collaborate with Congress to align the treatment of small molecule drugs with biological products, citing concerns about industry investment distortions and cost increases for Medicare and its beneficiaries.[2]
Competition Corner
|May 1, 2025
|2 Min Read
For companies operating in the U.S. consumer and retail space—whether in luxury goods, electronics, e-commerce, or mass retail—the current political and regulatory climate presents a shifting landscape of antitrust enforcement that’s worth watching closely.
Other Results 37 results
Law Glossary
What Is the Standard for the FDA to Grant a Generic Drug License?
An Abbreviated New Drug Application (ANDA) must contain evidence that the proposed generic drug product is bioequivalent to the reference drug.
Law Glossary
What Is the Approval Process for Generic Drugs?
Approval for generic drugs are governed by the Hatch-Waxman Act. The Hatch-Waxman Act provides the framework for an applicant to demonstrate that its proposed generic product is bioequivalent to the brand-name drug.
Location
Winston & Strawn’s São Paulo office reflects the firm’s long-term investment in Brazil and the significant commitment of Winston’s Latin America practice group members to the country over many decades. Our fully bilingual São Paulo-based attorneys represent clients on international financing, cross-border mergers and acquisitions, corporate governance, and disputes. They also act as a relationship touch point for global clients looking to expand into Brazil, ensuring an integrated and seamless service. Our São Paulo attorneys have in-depth knowledge of the region’s legal, cultural, political, regulatory, and commercial frameworks, which have earned them recognition from Chambers Global, Chambers Brazil, Chambers Latin America, Leaders League, The Legal 500, Latinvex, IFLR 1000, and LatinFinance, among many others.